Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes.


Cardiovascular outcome trials of antihyperglycaemic drugs and non-statin LDL-cholesterol-lowering drugs in patients with type 2 diabetes who have, or who are at high risk of, atherosclerotic cardiovascular disease have provided new evidence that has substantially affected the management of cardiovascular risk in these patients. On the basis of proven… (More)
DOI: 10.1016/S2213-8587(17)30033-5


6 Figures and Tables